Skip to main content
. Author manuscript; available in PMC: 2020 May 25.
Published in final edited form as: Leukemia. 2019 Nov 25;34(5):1354–1363. doi: 10.1038/s41375-019-0656-9

Figure 2. IGF2BP1 expression supports leukemia cancer stem cell properties.

Figure 2.

a, Schematic representation of ALDH− (depleted) and ALDH+ (enriched, 20.5%) sorted subpopulations of 697(EU3) (left); endogenous levels of IGF2BP1 mRNA and protein in 697(EU3) ALDH− and ALDH+ cells (t-test, **P<0.01, n=3, ± SEM); b, Expression of selected leukemia stem cell markers in MOLT16 with overexpression of IGF2BP1 and GFP control (t-test, *P<0.05, ***P<0.001, n=3, ± SEM); c, Representative flow cytometric analysis of Ki67 staining of 697(EU3) ALDH− and ALDH+ subpopulations, and ALDH+ cells with IGF2BP1 knockdown (SH2), and Kaplan-Meier survival analysis of mice injected with 1×103 of those cells (Mantel-Cox test, **P=0.0067, ****P<0.0001, n=4).